High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors
Yuka Kinoshita(University of Tokyo Hospital), Seiji Fukumoto(Tokushima Hospital), Yusuke Shinoda(The University of Tokyo), Nobuaki Ito(University of Tokyo Hospital), Yuichi Takashi(Fukuoka University), Noriko Makita(University of Occupational and Environmental Health Japan), Makoto Arai(Chiba University), Masaomi Nangaku(The University of Tokyo)
Cited by 31
Related Papers
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
|Journal of Clinical Oncology|2019|168
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
|Calcified Tissue International|2019|160
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2017|149
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment
|Endocrine Reviews|2018|148